SARS-CoV-2 Spike Protein Influences Expression of ICOSL and ICAM-2 in Prostate Cancer

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus responsible for the COVID-19 pandemic. The viral protein of SARS-CoV-2, spike protein (SP), mediates entry into host cells, contributing to pathogenesis of COVID-19. Prostate cancer is the most common cancer among men in the United States. Inducible T-cell costimulator ligand (ICOSL) and intercellular cell adhesion molecule 2 (ICAM-2) are expressed in cancer cells and their roles in cancer growth remain controversial. It is unknown if SP can affect the expression of ICAM-2 or ICOSL in prostate cancer. This study investigated the effects of SARS-CoV-2 SP on the expression of ICAM-2 and ICOSL and the time-dependent effect of SP on growth and survival of prostate cancer cells. Methods: The effect of SARS-CoV-2 SP on the survival of a widely-used prostate cancer cell line, LNCaP, was assessed using clonogenic cell survival assay and quick cell proliferation assay. Reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC) were performed to investigate the expression of ICAM-2 and ICOSL. The survival of an additional prostate cancer cell line, PC-3, was also evaluated by clonogenic survival assay. Results: After 3 days, a significant decrease in the percentage of colonies in LNCaP cells treated with SP was found, which was paralleled by a decrease in optical density (OD) value in LNCaP cells in the presence of SP. A significant decrease in the percentage of colonies treated with SP was also found in PC-3 cells evaluated by clonogenic survival assay. In addition, the mRNA expression of ICAM-2 was lower, whereas the mRNA expression of ICOSL was higher in SP-treated LNCaP cells. This was supported by protein expressions for ICAM-2 and ICOSL evaluated with IHC. Conclusions: In LNCaP cells, SARS-CoV-2 SP downregulates the expression of ICAM-2 but upregulates the expression of ICOSL. SARS-CoV-2 SP inhibits growth of prostate cancer cells in a time-dependent manner. Further studies are needed to fully address the roles of ICAM-2 and ICOSL in the inhibition prostate cancer growth by SARS-CoV-2 SP.

SARS-CoV-2; spike protein; prostate cancer; ICAM-2; ICOSL

[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022; 72: 7–33.

[2] Perdana NR, Mochtar CA, Umbas R, Hamid ARA. The Risk Factors of Prostate Cancer and Its Prevention: A Literature Re-view. Acta Medica Indonesiana. 2016; 48: 228–238.

[3] Litwin MS, Tan H. The Diagnosis and Treatment of Prostate Cancer. Journal of the American Medical Association. 2017; 317: 2532–2542.

[4] Datta K, Muders M, Zhang H, Tindall DJ. Mechanism of lymph node metastasis in prostate cancer. Future Oncology. 2010; 6: 823–836.

[5] Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Current Opinion in Genetics & Development. 2008; 18: 11–18.

[6] Bates JP, Derakhshandeh R, Jones L, Webb TJ. Mechanisms of immune evasion in breast cancer. BMC Cancer. 2018; 18: 556.

[7] Houghton AN, Guevara-Patiño JA. Immune recognition of self in immunity against cancer. Journal of Clinical Investigation. 2004; 114: 468–471.

[8] Yang L, Li A, Lei Q, Zhang Y. Tumor-intrinsic signaling path-ways: key roles in the regulation of the immunosuppressive tumor microenvironment. Journal of Hematology & Oncology. 2019; 12: 125.

[9] Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in can-cer immunosuppression — implications for anticancer therapy. Nature Reviews Clinical Oncology. 2019; 16: 356–371.

[10] Hinshaw DC, Shevde LA. The Tumor Microenvironment In-nately Modulates Cancer Progression. Cancer Research. 2019; 79: 4557–4566.

[11] Chattopadhyay K, Lazar-Molnar E, Yan Q, Rubinstein R, Zhan C, Vigdorovich V, et al. Sequence, structure, function, immu-nity: structural genomics of costimulation. Immunological Re-views. 2009; 229: 356–386.

[12] Schildberg F, Klein S, Freeman G, Sharpe A. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity. 2016; 44: 955–972.

[13] Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999; 397: 263–266.

[14] Khayyamian S, Hutloff A, Büchner K, Gräfe M, Henn V, Kroczek RA, et al. ICOS-ligand, expressed on human endothe-lial cells, costimulates Th1 and Th2 cytokine secretion by mem-ory CD4+ T cells. Proceedings of the National Academy of Sci-ences of the United States of America. 2002; 99: 6198–6203.

[15] Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revis-ited. Annual Review of Immunology. 2005; 23: 515–548.

[16] Martin-Orozco N, Li Y, Wang Y, Liu S, Hwu P, Liu Y, et al. Melanoma Cells Express ICOS Ligand to Promote the Acti-vation and Expansion of T-Regulatory Cells. Cancer Research. 2010; 70: 9581–9590.

[17] Wang B, Jiang H, Zhou T, Ma N, Liu W, Wang Y, et al. Expres-sion of ICOSL is associated with decreased survival in invasive breast cancer. PeerJ. 2019; 7: e6903.

[18] Solinas C, Gu-Trantien C, Willard-Gallo K. The rationale be-hind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open. 2020; 5: e000544.

[19] de Fougerolles AR, Qin X, Springer TA. Characterization of the function of intercellular adhesion molecule (ICAM)-3 and com-parison with ICAM-1 and ICAM-2 in immune responses. Jour-nal of Experimental Medicine. 1994; 179: 619–629.

[20] Staunton DE, Dustin ML, Springer TA. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature. 1989; 339: 61–64.

[21] Johns Hopkins University. Coronavirus Resource Center. 2021. Available at: https://coronavirus.jhu.edu/map.htmlSurn ame (Accessed: 15 February 2022).

[22] Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. The Lancet. 2020; 395: 470–473.

[23] Fehr AR, Perlman S. Coronaviruses: an Overview of their Repli-cation and Pathogenesis. Coronaviruses. 2015; 1282: 1–23.

[24] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181: 271–280.e8.

[25] Dong M, Zhang J, Ma X, Tan J, Chen L, Liu S, et al. ACE2, TM-PRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomedicine & Pharmacotherapy. 2020; 131: 110678.

[26] Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Frontiers of Medicine. 2020; 14: 185–192.

[27] Johnson BD, Zhu Z, Lequio M, Powers CGD, Bai Q, Xiao H, et al. SARS-CoV-2 spike protein inhibits growth of prostate can-cer: a potential role of the COVID-19 vaccine killing two birds with one stone. Medical Oncology. 2022; 39: 32.

[28] Fang Y, Herrick EJ, Nicholl MB. A Possible Role for Perforin and Granzyme B in Resveratrol-Enhanced Radiosensitivity of Prostate Cancer. Journal of Andrology. 2012; 33: 752–760.

[29] Fang Y, Bradley MJ, Cook KM, Herrick EJ, Nicholl MB. A po-tential role for resveratrol as a radiation sensitizer for melanoma treatment. Journal of Surgical Research. 2013; 183: 645–653.

[30] Fang Y, Moore BJ, Bai Q, Cook KM, Herrick EJ, Nicholl MB. Hydrogen peroxide enhances radiation-induced apoptosis and inhibition of melanoma cell proliferation. Anticancer Research. 2013; 33: 1799–1807.

[31] Zhu Z, Davidson KT, Brittingham A, Wakefield MR, Bai Q, Xiao H, et al. Trichomonas vaginalis: a possible foe to prostate cancer. Medical Oncology. 2016; 33: 115.

[32] Sham N, Qin C, Zhu Z, Redington CG, Xiao H, Bai Q, et al. Raspberry Extract with Potential Antitumor Activity against Cervical Cancer. Anticancer Research. 2021; 41: 3343–3348.

[33] Nicholl MB, Chen X, Qin C, Bai Q, Zhu Z, Davis MR, et al. IL-32α has differential effects on proliferation and apoptosis of human melanoma cell lines. Journal of Surgical Oncology. 2016; 113: 364–369.

[34] Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. Multiple actions of steroid hormones–a focus on rapid, nonge-nomic effects. Pharmacological Reviews. 2000; 52: 513–556.

[35] Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent pro-static cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Research. 1997; 57: 4511–4516.

[36] Groux H. Type 1 T-regulatory cells: their role in the control of immune responses1. Transplantation. 2003; 75: 8S–12S.

[37] Ito T, Hanabuchi S, Wang Y, Park WR, Arima K, Bover L, et al. Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and Periphery. Immunity. 2008; 28: 870–880.

[38] Vocanson M, Rozieres A, Hennino A, Poyet G, Gaillard V, Re-naudineau S, et al. Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells. Journal of Allergy and Clini-cal Immunology. 2010; 126: 280–289.e7.

[39] Strauss L, Bergmann C, Szczepanski MJ, Lang S, Kirkwood JM, Whiteside TL. Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implica-tions and impact on tumor-mediated immune suppression. Jour-nal of Immunology. 2008; 180: 2967–2980.

[40] Huang X, Liu X, Lin X, Yu H, Sun J, Liu X, et al. Role of plas-macytoid dendritic cells and inducible costimulator‐positive reg-ulatory T cells in the immunosuppression microenvironment of gastric cancer. Cancer Science. 2014; 105: 150–158.

[41] Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C, et al. ICOS-Ligand Expression on Plasmacytoid Den-dritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells. Can-cer Research. 2012; 72: 6130–6141.

[42] Han Y, Dong Y, Yang Q, Xu W, Jiang S, Yu Z, et al. Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells. Frontiers in Immunology. 2018; 9: 2227.

[43] Le K, Thibult M, Just-Landi S, Pastor S, Gondois-Rey F, Granjeaud S, et al. Follicular B Lymphomas Generate Regula-tory T Cells via the ICOS/ICOSL Pathway and are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy. Cancer Research. 2016; 76: 4648–4660.

[44] Mo L, Chen Q, Zhang X, Shi X, Wei L, Zheng D, et al. De-pletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer. Vaccine. 2017; 35: 5932–5938.

[45] Miller AM, Lundberg K, Ozenci V, Banham AH, Hellström M, Egevad L, et al. CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients. Journal of Immunology. 2006; 177: 7398–7405.

[46] Zhang G, Xu Y, Zhang S, Zhou H. The ICOSL Expression Pre-dicts Better Prognosis for Nasopharyngeal Carcinoma via En-hancing Oncoimmunity. BioMed Research International. 2020; 2020: 9756732.

[47] Marinelli O, Nabissi M, Morelli MB, Torquati L, Amantini C, Santoni G. ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy. Current Protein & Peptide Science. 2018; 19: 1107–1113.

[48] Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, et al. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. Cancer Research. 2016; 76: 3684–3689.

[49] Harjunpää H, Llort Asens M, Guenther C, Fagerholm SC. Cell Adhesion Molecules and Their Roles and Regulation in the Im-mune and Tumor Microenvironment. Frontiers in Immunology. 2019; 10: 1078.

[50] Tanaka H, Yashiro M, Sunami T, Sakate Y, Kosaka K, Hirakawa K. ICAM-2 gene therapy for peritoneal dissemination of scir-rhous gastric carcinoma. Clinical Cancer Research. 2004; 10: 4885–4892.

[51] Liu Z, Guo B, Lopez RD. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensi-tivity of pancreatic cancer cells to cytolysis by human γδ-T cells: Implications in the design of γδ-T-cell-based immunotherapies for pancreatic cancer. Journal of Gastroenterology and Hepatol-ogy. 2009; 24: 900–911.

[52] Somersalo K, Carpén O, Saksela E, Gahmberg CG, Nortamo P, Timonen T. Activation of Natural Killer Cell Migration by Leukocyte Integrin-binding Peptide from Intracellular Adhesion Molecule-2 (ICAM-2). Journal of Biological Chemistry. 1995; 270: 8629–8636.

[53] CARPENITO C, PYSZNIAK AM, TAKEI F. ICAM‐2 Provides a Costimulatory Signal for T Cell Stimulation by Allogeneic Class II MHC. Scandinavian Journal of Immunology. 1997; 45: 248–254.

[54] Yoon KJ, Phelps DA, Bush RA, Remack JS, Billups CA, Khoury JD. ICAM-2 expression mediates a membrane-actin link, con-fers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma. PLoS ONE. 2008; 3: e3629.

[55] Roland CL, Harken AH, Sarr MG, Barnett CC. ICAM-1 expres-sion determines malignant potential of cancer. Surgery. 2007; 141: 705–707.

[56] Li D, Jin M, Bao P, Zhao W, Zhang S. Clinical Characteristics and Results of Semen Tests among Men with Coronavirus Dis-ease 2019. JAMA Network Open. 2020; 3: e208292.

[57] George S, Pal AC, Gagnon J, Timalsina S, Singh P, Vydyam P, et al. Evidence for SARS-CoV-2 Spike Protein in the Urine of COVID-19 Patients. Kidney360. 2021; 2: 924–936.

[58] Song H, Seddighzadeh B, Cooperberg MR, Huang FW. Expres-sion of ACE2, the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells. European Urology. 2020; 78: 296–298.

[59] Cheng J, Zhou J, Fu S, Fu J, Zhou B, Chen H, et al. Prostate adenocarcinoma and COVID-19: The possible impacts of TM-PRSS2 expressions in susceptibility to SARS-CoV-2. Journal of Cellular and Molecular Medicine. 2021; 25: 4157–4165.

[60] Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Cata-pano CV, et al. Androgen-deprivation therapies for prostate can-cer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Annals of Oncology. 2020; 31: 1040–1045.

[61] Ogata AF, Maley AM, Wu C, Gilboa T, Norman M, Lazarovits R, et al. Ultra-Sensitive Serial Profiling of SARS-CoV-2 Anti-gens and Antibodies in Plasma to Understand Disease Progres-sion in COVID-19 Patients with Severe Disease. Clinical Chem-istry. 2020; 66: 1562–1572.

[62] Ogata AF, Cheng CA, Desjardins M, Senussi Y, Sherman AC, Powell M, et al. Circulating SARS-CoV-2 Vaccine Antigen De-tected in the Plasma of mRNA-1273 Vaccine Recipients. Clini-cal Infectious Disease. 2022; 74: 715–718.